References
- Vachon JGV, Siu W. Tuberculosis in Canada, 2016. Can Commun Dis Rep. 2018;44(3/4):75–9.
- Inuit Tapariit Kanatami. TB elimination among Inuit communities. 2018. Available from: https://www.itk.ca/the-government-of-canada-and-inuit-tapiriit-kanatami-commit-to-eliminating-tuberculosis-across-inuit-nunangat-by-2030/
- Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34:271–286.
- Dehghani K, Lan Z, Li P, et al. Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study. Lancet Public Health. 2018;3(3):e133–e42. .
- Liu Y, Birch S, Newbold KB, et al. Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature. Int J Health Plann Manage. 2018;33(2):e416–e33.
- Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–1278.
- Inuit Tapariit Kanatami. Inuit statistical profile. 2018. Available from: https://www.google.ca/search?q=Inuit+Statistical+Profile+2018&rlz=1C1NHXL_enCA721CA721&oq=Inuit+Statistical+Profile+2018&aqs=chrome.69i57.1406j0j7&sourceid=chrome¡UTF-8
- Patterson M, Finn S, Barker K. Addressing tuberculosis among Inuit in Canada. Can Commun Dis Rep. 2018;44(3/4):82–85.
- World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf;jsessionid=E95EF4C8614F4FD6C7527D831402EEF4?sequence=1
- Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166. .
- Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247–255.
- Sun HY, Huang YW, Huang WC, et al. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis (Edinb). 2018;111:121–126.
- Sandul AL, Nwana N, Holcombe JM, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–1093. .
- Schmit KM, Lobato MN, Lang SG, et al. High completion rate for 12 weekly doses of isoniazid and rifapentine as treatment for latent mycobacterium tuberculosis infection in the federal bureau of prisons. J Public Health Manag Pract. 2019;25(2):E1–E6.
- Nwana N, Marks SM, Lan E, et al. Treatment of latent mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness. PLoS One. 2019;14(3):e0213524.
- Schein YL, Madebo T, Andersen HE, et al. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis. 2018;18(1):587. .
- Froberg G, Jansson L, Bruchfeld J. Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice. Eur Respir J. 2019;53:2.
- Macaraig MM, Jalees M, Lam C, et al. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018;22(11):1344–1349.
- Pease C, Hutton B, Yazdi F, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265. .
- Pease C, Hutton B, Yazdi F, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–566. .
- Borisov AS1, Bamrah Morris S1, Njie GJ1, Winston CA1, Burton D1, Goldberg S1, Yelk Woodruff R1, Allen L1, LoBue P1, Vernon A1. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):723–726. doi: https://doi.org/10.15585/mmwr.mm6725a5.
- Government of Canada. List of drugs for an urgent public health need 2018. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/access-drugs-exceptional-circumstances/list-drugs-urgent-public-health-need.html
- Pease C, Zwerling A, Mallick R, et al. The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012-2016. BMC Infect Dis. 2019;19(1):890. .
- Nunavut Bureau of Statistics. Population Estimates 2018 Available from: http://www.stats.gov.nu.ca/en/Population%20estimate.aspx
- Ramsay CR, Matowe L, Grilli R, et al. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care. 2003;19(4):613–623.
- Sterling TR, Moro RN, Borisov AS, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61(4):527–535.
- Stennis NL, Burzynski JN, Herbert C, et al. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City health department clinics. Clin Infect Dis. 2016;62(1):53–59.
- Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252(14):1905–1907.